ID M3YK35_MUSPF Unreviewed; 720 AA.
AC M3YK35;
DT 01-MAY-2013, integrated into UniProtKB/TrEMBL.
DT 01-MAY-2013, sequence version 1.
DT 27-MAR-2024, entry version 58.
DE SubName: Full=NF-kappa-B inhibitor zeta {ECO:0000313|RefSeq:XP_004772043.1};
DE SubName: Full=NFKB inhibitor zeta {ECO:0000313|Ensembl:ENSMPUP00000011692.1};
GN Name=NFKBIZ {ECO:0000313|Ensembl:ENSMPUP00000011692.1,
GN ECO:0000313|RefSeq:XP_004772043.1};
OS Mustela putorius furo (European domestic ferret) (Mustela furo).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC Eutheria; Laurasiatheria; Carnivora; Caniformia; Musteloidea; Mustelidae;
OC Mustelinae; Mustela.
OX NCBI_TaxID=9669 {ECO:0000313|Ensembl:ENSMPUP00000011692.1};
RN [1] {ECO:0000313|Ensembl:ENSMPUP00000011692.1}
RP IDENTIFICATION.
RG Ensembl;
RL Submitted (MAR-2023) to UniProtKB.
RN [2] {ECO:0000313|RefSeq:XP_004772043.1}
RP IDENTIFICATION.
RC TISSUE=Brain {ECO:0000313|RefSeq:XP_004772043.1};
RG RefSeq;
RL Submitted (NOV-2023) to UniProtKB.
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; AEYP01077978; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR RefSeq; XP_004772043.1; XM_004771986.3.
DR STRING; 9669.ENSMPUP00000011692; -.
DR Ensembl; ENSMPUT00000011884.1; ENSMPUP00000011692.1; ENSMPUG00000011786.1.
DR GeneID; 101675384; -.
DR KEGG; mpuf:101675384; -.
DR CTD; 64332; -.
DR eggNOG; KOG0504; Eukaryota.
DR GeneTree; ENSGT00940000153695; -.
DR HOGENOM; CLU_030240_0_0_1; -.
DR OMA; LQRNQQH; -.
DR OrthoDB; 5406967at2759; -.
DR Proteomes; UP000000715; Unplaced.
DR GO; GO:0036464; C:cytoplasmic ribonucleoprotein granule; IEA:Ensembl.
DR GO; GO:0016607; C:nuclear speck; IEA:Ensembl.
DR GO; GO:0070974; F:POU domain binding; IEA:InterPro.
DR GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IEA:Ensembl.
DR GO; GO:0003712; F:transcription coregulator activity; IEA:Ensembl.
DR GO; GO:0042100; P:B cell proliferation; IEA:Ensembl.
DR GO; GO:1990117; P:B cell receptor apoptotic signaling pathway; IEA:Ensembl.
DR GO; GO:0097398; P:cellular response to interleukin-17; IEA:Ensembl.
DR GO; GO:0071222; P:cellular response to lipopolysaccharide; IEA:Ensembl.
DR GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; IEA:Ensembl.
DR GO; GO:0006338; P:chromatin remodeling; IEA:Ensembl.
DR GO; GO:0002544; P:chronic inflammatory response; IEA:Ensembl.
DR GO; GO:0019221; P:cytokine-mediated signaling pathway; IEA:Ensembl.
DR GO; GO:0050829; P:defense response to Gram-negative bacterium; IEA:Ensembl.
DR GO; GO:1904019; P:epithelial cell apoptotic process; IEA:Ensembl.
DR GO; GO:0061436; P:establishment of skin barrier; IEA:Ensembl.
DR GO; GO:0097194; P:execution phase of apoptosis; IEA:Ensembl.
DR GO; GO:0048873; P:homeostasis of number of cells within a tissue; IEA:Ensembl.
DR GO; GO:0090594; P:inflammatory response to wounding; IEA:Ensembl.
DR GO; GO:0045190; P:isotype switching; IEA:Ensembl.
DR GO; GO:0032980; P:keratinocyte activation; IEA:Ensembl.
DR GO; GO:0030216; P:keratinocyte differentiation; IEA:Ensembl.
DR GO; GO:0043616; P:keratinocyte proliferation; IEA:Ensembl.
DR GO; GO:0042789; P:mRNA transcription by RNA polymerase II; IEA:Ensembl.
DR GO; GO:0002317; P:plasma cell differentiation; IEA:Ensembl.
DR GO; GO:0050729; P:positive regulation of inflammatory response; IEA:Ensembl.
DR GO; GO:2000321; P:positive regulation of T-helper 17 cell differentiation; IEA:Ensembl.
DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IEA:Ensembl.
DR GO; GO:0072718; P:response to cisplatin; IEA:Ensembl.
DR GO; GO:0051593; P:response to folic acid; IEA:Ensembl.
DR GO; GO:0140459; P:response to Gram-positive bacterium; IEA:Ensembl.
DR GO; GO:0009410; P:response to xenobiotic stimulus; IEA:Ensembl.
DR GO; GO:0048536; P:spleen development; IEA:Ensembl.
DR GO; GO:0002456; P:T cell mediated immunity; IEA:Ensembl.
DR GO; GO:0050852; P:T cell receptor signaling pathway; IEA:Ensembl.
DR GO; GO:0045063; P:T-helper 1 cell differentiation; IEA:Ensembl.
DR GO; GO:0072539; P:T-helper 17 cell differentiation; IEA:Ensembl.
DR GO; GO:0002224; P:toll-like receptor signaling pathway; IEA:Ensembl.
DR GO; GO:0070897; P:transcription preinitiation complex assembly; IEA:Ensembl.
DR Gene3D; 1.25.40.20; Ankyrin repeat-containing domain; 1.
DR InterPro; IPR002110; Ankyrin_rpt.
DR InterPro; IPR036770; Ankyrin_rpt-contain_sf.
DR InterPro; IPR047571; OCA.
DR PANTHER; PTHR24124; ANKYRIN REPEAT FAMILY A; 1.
DR PANTHER; PTHR24124:SF5; NF-KAPPA-B INHIBITOR ZETA; 1.
DR Pfam; PF12796; Ank_2; 2.
DR PRINTS; PR01415; ANKYRIN.
DR SMART; SM00248; ANK; 6.
DR SUPFAM; SSF48403; Ankyrin repeat; 1.
DR PROSITE; PS50297; ANK_REP_REGION; 3.
DR PROSITE; PS50088; ANK_REPEAT; 3.
DR PROSITE; PS52003; OCA; 1.
PE 4: Predicted;
KW ANK repeat {ECO:0000256|PROSITE-ProRule:PRU00023};
KW Reference proteome {ECO:0000313|Proteomes:UP000000715}.
FT DOMAIN 108..130
FT /note="OCA"
FT /evidence="ECO:0000259|PROSITE:PS52003"
FT REPEAT 481..513
FT /note="ANK"
FT /evidence="ECO:0000256|PROSITE-ProRule:PRU00023"
FT REPEAT 614..646
FT /note="ANK"
FT /evidence="ECO:0000256|PROSITE-ProRule:PRU00023"
FT REPEAT 650..686
FT /note="ANK"
FT /evidence="ECO:0000256|PROSITE-ProRule:PRU00023"
FT REGION 1..22
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT REGION 46..94
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT REGION 188..212
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT REGION 291..322
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 55..81
FT /note="Polar residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ SEQUENCE 720 AA; 78047 MW; B65863BDC26951BB CRC64;
MIVDKLLDDS RGGEGLLDTA GDGGLMTSPL NLAYFYGASP PAAAPGACDA VCSSSGPSAP
GSPGSDSSDF SSASSVSSCG AVESRPRGGA RAERLQVEPH MGVGRQQRGP FQGVRVKNSV
KELLLHIRSH KQKASGQAVD DLKTQSVNRE QFTELKNVVP FSGKRKGPDS LSDGPACKRP
ALLHTQFLTP PQTPTPAESM EDVHHSESKQ DSSADLLQNI INIKNECSPV SLNTVQVSWM
SPGVVPQGSP REQCQDFHRG QIFSPPQKYQ PFQVGSSLHL VDQAALYQYS PQSQNLQPPP
PQHYTHAPAL EYSPYPGASQ SPSYEPNLFD GQEPQFCPDQ SFASLLNSRE SENIAVPIQN
SPSVQQQNDG HLQNFSMMPP SACEAMPSHD AGSAPLSTSL PFPNIIGNPV STTQLGKSFF
QWQVEQEESK LANISQDQFL SKDADGDTFL HIAVAQGRRA LSYVLARKMN ALHMLDIKEH
NGQSAFQVAV AANQHLIVQD LVNLGAQVNT TDCWGRTPLH VCAEKGHSQV LQAIQKGAAK
SNQFLDLEAT NYDGLTPLHC AVVAHNAVVH ELQRNQQPHL PEVQELLLKN KSLVDTIKCL
IQMGAAVEAK DRKSGRTALH LAAEEANLEL IRLFLELPSC LSFVNAKAYN GNTALHVAAS
LQYRVTQLDA VRLLMRKGAD PSTRNLENEQ PVHLVPDGPV GEQIRRILKG KSIQQRAPPY
//
